Ewing sarcoma: what trends in recent works? A holistic analysis with global productivity: A cross-sectional study

Abstract

Advances in the biology of Ewing sarcoma, which continues to be an important cause of mortality, have caused an increase in information in the literature related to the underlying molecular base of the disease and discussions of new treatment approaches. In this study, we aimed to comprehensively analyze the published scientific articles on Ewing sarcoma. The Web of Science database was used to obtain and statistically analysis articles on Ewing sarcoma that were published between 1980 and 2021. Maps of network visualization were used to reveal trending topics, global collaborations, and the most effective studies. Correlation analysis was performed using Spearman's correlation coefficient. A total of 3236 articles were analyzed. The first 3 countries that contributed the most to the literature and cooperated most intensively were USA (1194, 36.8%), Germany (293, 9%), Italy (254, 7.8%). Pediatric Blood & Cancer (n = 122), Cancer (87), Journal of Pediatric Hematology Oncology (71) were among the top 3 journals with the most articles. The most active author was Piero Picci (n = 94). High-income countries have a great effect on the literature on this subject. The most studied trend topics in recent years were pediatric oncology, EWS RNA Binding Protein 1 (EWSR1), EWSR1-FL1, epigenetics, bioinformatics, microRNA, gene expression, metastasis, migration, biomarker, immunotherapy, survival, outcomes, surveillance epidemiology and end results (SEER), nomogram, temozolomide, irinotecan, and drug resistance. Genetic studies, metastasis, immunotherapy, life analyses/nomogram based on new data obtained from SEER, and chemotherapy with irinotecan and temozolomide combination, were seen to be the topics researched in recent years.Abbreviations: ES = Ewing sarcoma, EWSR1 = EWS RNA Binding Protein 1, GDP = gross domestic product, GDP per capita = gross domestic product per capita, HDI = human development index, NC = number of co-citation, SCI-Expanded = Science Citation Index Expanded, SEER = surveillance epidemiology and end results.

The evolution of primary hyperparathyroidism publications and global productivity from past to present: A bibliometric analysis during 1980 to 2022

“…Compared to other databases, the WoS includes articles published in higher impact journals (almost all SCI-E). [14,31] The preference for the use of WoS in this study was also influenced by the widespread use of WoS in other bibliometric studies in literature. [14–20,31] A second limitation of our study is the exclusion of articles published in 2023 from the analyses.…”

“…[14,31] The preference for the use of WoS in this study was also influenced by the widespread use of WoS in other bibliometric studies in literature. [14–20,31] A second limitation of our study is the exclusion of articles published in 2023 from the analyses. However, it should be noted that in other bibliometric studies conducted in the literature, [17–20] articles published within an incomplete year are also not included in the analyses.…”

Ewing sarcoma with intra thoracic and multiple extra thoracic metastases in a young adult male: A case report

“…Ewing sarcoma (ES), which was first described in 1921 by James Ewing, is a small, round, blue-cell mesenchymal malignancy [ 7 ]. Ewing sarcoma is a malignant bone tumor (occurring predominantly in the pelvis, femur, tibia, and ribs) or soft-tissue tumor (occurring predominantly in the thoracic wall, gluteal muscle, pleural cavities, and cervical muscles) that mainly affects children, adolescents, and young adults (AYAs), with 1.5 cases per million children and AYAs globally.…”

“…As a treatment strategy for ES, four types of standard treatment are used: surgery, radiation therapy, chemotherapy, and high-dose chemotherapy with stem cell salvage. For successful treatment, extremely intense chemotherapy is required together with surgery and/or radiation [ 7 ]. Broadly, systemic therapy is the cornerstone of treatment for all Ewing sarcoma patients.…”

“…The most common regions of metastasis are the lungs and pleural cavity [ 15 ], the skeletal system, and bone marrow, or a combination of these. The most important prognostic factor in ES is metastasis, and while the 5-year survival rate is approximately 70 % when there is no metastasis, this rate falls to around 30 % when metastasis and/or recurrence are present [ 7 ]. Mousavi et al (2022) reported a case of metastatic thoracic and lumbar intramedullary and extramedullary Ewing sarcoma [ 16 ].…”